UK MHRA Issues Landmark Infringement Notice To Celixir Over Serious Clinical Trial Violations

The UK’s drug regulator said that a trial run by cell therapy firm Celixir “risked seriously jeopardizing the rights, safety and wellbeing of trial participants” after an inspection discovered expired product batches, unauthorized dosing and other serious breaches.